Entrada Therapeutics Inc (TRDA) FinancialsTRDAEntrada Therapeutics Inc

Evaluating the bottom line, Entrada Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5007.02%, while the net margin is -4762.03%. These profitability ratios, combined with a Return on Equity (ROE) of -54.09%, provide a clear picture of how effectively TRDA converts its operational activities into shareholder value.

In the context of the broader market, TRDA competes directly with industry leaders such as ALXO and AVXL. With a market capitalization of $290.47M, it holds a significant position in the sector. When comparing efficiency, TRDA's gross margin of 100.00% stands against ALXO's N/A and AVXL's N/A. Such benchmarking helps identify whether Entrada Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% across recent quarters, but it has also reported substantial net losses, with a net loss of $42.76 million in Q2 2026 and a forward P/E ratio of 3333.33, indicating extreme valuation concerns.